 |
|
|
| |
Safety, pharmacokinetics, and exploratory efficacy of the PD-1 inhibitor budigalimab in antiretroviral treatment-suppressed people living with HIV-1: preliminary analysis of 2 Phase 1b studies including an analytical treatment interruption
|
| |
| |
oral at EACS 2023 Oct 20
|
| |
|
|
|
|
|
